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In heart failure prognosis is related to the
severity of impairment of functional capa-
city.1 The peak oxygen consumption (VO2)
at cardiopulmonary exercise test (CPET) is
considered the gold standard for the
evaluation of exercise tolerance; neverthe-
less, its clinical application is limited. The 6-
minute walk test (6MWT) has been
proposed as a simple, inexpensive, repro-
ducible alternative to the CPET. The
6MWT reproduces the activity of daily life
and this is particularly relevant in elderly
patients who usually develop symptoms
below their theoretical maximal exercise
capacity.2 The test showed a good reprodu-
cibility and is largely independent from
aetiology of heart failure, NYHA class and
indices of left ventricular systolic or dia-
stolic function measured at rest.3
Peak VO2 and distance walked at
6MWT have been demonstrated to have
a non-linear relation and, in particular, a
wide variation has been shown for pVO2
values between 10 ml/min/kg and 20 ml/
min/kg. A closer relation exists in more
severe heart failure. The incremental
workload nature of CPET may result in
an earlier muscular exhaustion in patients
with more severe disease, who otherwise
may better perform in a stable workload
test such as the 6MWT.
In this issue of Heart two papers deals
with different aspects of the usefulness and
prognostic value of 6MWT in patients
undergoing aortic valve replacement
(AVR) (see pages 113 and 118).
In patients from the ASSERT study, in
which stentless versus stented AVR was
compared, 208 subjects with severe aortic
stenosis underwent 6MWT before surgery
and then were followed for 12 months.4
Composite endpoint of death, myocardial
infarction and stroke was 13% in patients
who walked (300 metres in comparison
to 4% in those walking .300 metres.
Distance walked at 6MWT provided
further prognostic information to additive
Euroscore risk calculation and was the
only independent variable related to
increased risk of composite endpoint.
Rimington et al evaluated the baseline
predictors of improvement of functional
capacity and health-related quality of life
at 12-month follow-up in 225 patients
undergoing their first AVR.5 Distance
walked at 6MWT after AVR significantly
increased. The improvement in distance
walked was independently related to
preoperative walking distance, age and
IPQ-R treatment control. Preoperative
walking distance contributed to 36% of
the overall 44% change of variance. Also
quality of life significantly improved after
AVR and preoperative PCS and walking
distance were the only independent vari-
ables at 12-month follow-up.
Results of previous investigations eval-
uating the independent prognostic value
of 6MWT in heart failure as in other
different clinical conditions (aortic steno-
sis, primary pulmonary hypertension,
various pulmonary diseases) gave con-
trasting results. The wide differences in
examined populations may in part
account for reported differences.
In patients with heart failure the prog-
nostic value of 6MWT was first reported
from a substudy of SOLVD investigation.6
Mortality was threefold in patients who
walked ,350 metres in comparison to those
walking .450 metres. Ejection fraction and
the distance walked resulted independent
predictors of mortality or hospitalisation.
Roul et al7 in mild to moderate heart failure
did not find significant differences in dis-
tances at 6MWT between those who
reached the endpoint of death or hospitalisa-
tion for heart failure in comparison to the
event-free group, while pVO2 was signifi-
cantly higher in event-free patients.
Nevertheless the subgroup walking
,300 metres had an higher rate of death
and hospitalisation. The relation between
pVO2 and distance at 6MWT was closer
(r = 0.65) in these patients than in the whole
group (r = 0.21), suggesting that in more
severe disease 6MWT approached maximal
exercise capacity. In a similar population
walking a distance of ,350 metres levels of
brain natriuretic peptide (BNP), ischaemic
aetiology and atrial fibrillation were reported
to be independently related to prognosis.8
Opasich et al followed 270 patients
with chronic heart failure (CHF) for a
minimum of 6 months: 21% died or
underwent transplantation.9 Although
distance at 6MWT was significantly
associated with survival at univariate
analysis, predictive value was lost at
multivariate analysis. The absence of a
statistical significance of pVO2 and cate-
gorised distance at 6MWT when they are
considered together in a bivariate model
suggested that these two variables give
similar diagnostic information.
Rostagno et al investigated a group of
patients with mild to moderate heart
failure: event-free (death or heart trans-
plantation) survival at 36 months was
significantly lower, 62%, in patients walk-
ing ,300 metres in comparison to 82% of
those with intermediate (300–450 metres)
or high performance (.450 metres).10
Peak VO2 did not show a predictive value.
Only the 6MWT and left ventricular
ejection fraction (LVEF) were indepen-
dent prognostic factors.
In severe heart failure a distance below
the median (210 metres) was associated
with a 6-month mortality of 50% vs
20% in patients who covered a longer
distance,11 while a distance ,300 metres
predicted an increased likelihood of
death or hospitalisation for inotropic or
mechanical support within 6 months
but failed to predict overall or event-free
survival at 62 weeks.12 The predictive value
of 6MWT in patients with advanced heart
failure was questioned by other authors.13
Six-minute walk strata (,350 metres,
350–450 metres, .450 metres) were signif-
icantly associated with pVO2 strata (, or
.14 ml/kg/min; x2 = 29.5); however,
pVO2 was related to mortality whereas
the 6MWT was not.
It is difficult to assess that distance
walked at the 6MWT may be considered
an independent risk factor when another
objective test of functional capacity such
as CPET is used in the same population.
In fact, despite clear differences between
the two tests, the relation between pVO2
and distance walked at 6MWT was found
by most authors to be unreliable or that
they may not be independently related
prognostic factors at all. Most interesting
is the application of the 6MWT as a test
of functional cardiovascular capacity in
several clinical contexts, including the
preoperative evaluation of surgical risk
in different valvular surgery and heart
surgery that was not involving the valves.
Euroscore, as with other preoperative
score systems for surgical risk assess-
ment, is often relatively inaccurate, in
particular in patients with valvular heart
disease. Functional evaluation has been
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demonstrated to be more sensitive than
haemodynamic and echocardiographic
indexes in the prognostic evaluation of
heart failure from different aetiologies.
The inclusion in a preoperative clinical
evaluation of a simple and reproducible
test allowing assessment of cardiovascu-
lar performance should be investigated in
a large study with the aim of assessing if
it should be routinely employed not only
to evaluate immediate surgical risk but
also postoperative results in term of
mortality, expected exercise and improve-
ment of quality of life.
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